

# [Skp2 and its emerging role in the pathogenesis of systemic malignancies besides b...](https://assignbuster.com/skp2-and-its-emerging-role-in-the-pathogenesis-of-systemic-malignancies-besides-breast-carcinomas/)

[Health & Medicine](https://assignbuster.com/essay-subjects/health-n-medicine/)

A commentary on

Ben-Izhak, O., Akrish, S., Gan, S., and Nagler, R. M. (2009). Skp2 and salivary cancer. *Cancer Biol. Ther.* 8, 153–158.

Chang, H. C., Chang, F. R., Wang, Y. C., Pan, M. R., Hung, W. C., and Wu, Y. C. (2007). A bioactive with anolide tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression. *Mol. Cancer Ther.* 6, 1572–1578.

Hung, W. C., Tseng, W. L., Shiea, J., and Chang, H. C. (2010). Skp2 overexpression increases the expression of MMP-2 and MMP-9 and invasion of lung cancer cells. *Cancer Lett.* 288, 156–161.

Jiang, J., Pan, Y., Regan, K. M., Wu, C., Zhang, X., Tindall, D. J., et al. (2012). Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. *Prostate* 72, 225–232.

Lu, M., Zhao, Y., Xu, F., Wang, Y., Xiang, J., and Chen, D. (2012). The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer. *Med. Oncol* . PMID: 22714061. [Epub ahead of print].

Schuler, S., Diersch, S., Hamacher, R., Schmid, R. M., Saur, D., and Schneider, G. (2011). SKP2 confers resistance of pancreatic cancer cells towards TRAIL-induced apoptosis. *Int. J. Oncol.* 38, 219–225.

Shi, P., Zhang, Y., Tong, X., Yang, Y., and Shao, Z. (2011). Dihydrotestosterone induces p27 degradation via direct binding with SKP2 in ovarian and breast cancer. *Int. J. Mol. Med.* 28, 109–114.

Tang, Y., Simoneau, A. R., Liao, W. X., Yi, G., Hope, C., Liu, F., et al. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. *Mol. Cancer Ther.* 8, 458–468.

Wang, Z., Fukushima, H., Inuzuka, H., Wan, L., Liu, P., Gao, D., et al. (2012a). Skp2 is a promising therapeutic target in breast cancer. *Front. Oncol.* 1: 57. doi: 10. 3389/fonc. 2011. 00057

Wang, Z., Gao, D., Fukushima, H., Inuzuka, H., Liu, P., Wan, L., et al. (2012b). Skp2: a novel potential therapeutic target for prostate cancer. *Biochim. Biophys. Acta* 1825, 11–17.